

2019 international clinical practice guidelines for the treatment of venous thromboembolism in patients with cancer

Lancet Oncology, The  
20, e566-e581

DOI: [10.1016/s1470-2045\(19\)30336-5](https://doi.org/10.1016/s1470-2045(19)30336-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	How I treat cancer-associated thrombosis. <i>ESMO Open</i> , 2019, 4, e000610.	2.0	19
2	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. <i>Blood Advances</i> , 2019, 3, 3770-3779.	2.5	58
3	2019 international clinical practice guidelines for the treatment of venous thromboembolism. <i>Lancet Oncology</i> , The, 2019, 20, e655.	5.1	2
4	2019 international clinical practice guidelines for the treatment of venous thromboembolism â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e656.	5.1	25
5	A systematic review on the effects of direct oral anticoagulants on cancer growth and metastasis in animal models. <i>Thrombosis Research</i> , 2020, 187, 18-27.	0.8	18
6	Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. <i>Gastroenterology</i> , 2020, 158, 1346-1358.e4.	0.6	48
7	Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine. <i>Visceral Medicine</i> , 2020, 36, 280-287.	0.5	6
8	Primary prophylaxis of venous thromboembolism in extragonadal germ-cell tumour. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 90-92.	0.1	1
9	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. <i>Oncologist</i> , 2020, 25, 1075-1083.	1.9	9
11	La profilaxis de la enfermedad tromboemb3lica venosa en los pacientes con enfermedad m3dica. <i>Revista Clinica Espanola</i> , 2020, 220, 1-9.	0.2	2
12	Management of Cancer-Associated Thrombosis: An Evolving Area. <i>Cancers</i> , 2020, 12, 2999.	1.7	1
13	Evolving Treatment Options for Cancer-Related Venous Thromboembolism. <i>JACC: CardioOncology</i> , 2020, 2, 441-442.	1.7	4
14	How to screen and diagnose deep venous thrombosis (DVT) in patients hospitalized for or suspected of COVID-19 infection, outside the intensive care units. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 334-343.	0.1	8
15	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020, 196, 437-443.	0.8	0
16	Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. <i>The Cochrane Library</i> , 2020, 10, CD013399.	1.5	6
18	Single-Drug Approach with Edoxaban is Effective for Resolving Non-Acute Cancer-Associated Venous Thrombosis: A Single-Arm Retrospective Analysis. <i>Cancers</i> , 2020, 12, 1711.	1.7	1
19	Congr3's europ3en de canc3rologie et pratique officinale. <i>Actualites Pharmaceutiques</i> , 2020, 59, 37-41.	0.0	0
20	A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 848-859.	1.0	13

#	ARTICLE	IF	CITATIONS
22	Epidemiology and risk factors for cancer-associated thrombosis. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 6S3-6S7.	0.1	6
23	Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient). <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 6S17-6S23.	0.1	6
24	How to treat venous thromboembolism (TVE) in cancer patients: ten years of multidisciplinary team meetings (MDTM) at Saint-Louis Hospital. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 6S24-6S30.	0.1	1
25	Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 6S31-6S38.	0.1	8
26	Prevention of venous thromboembolism in ambulatory patients with cancer. <i>ESMO Open</i> , 2020, 5, e000948.	2.0	16
27	SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients. <i>Cancers</i> , 2020, 12, 3316.	1.7	23
28	Inpatient prophylaxis in cancer patients: where is the evidence?. <i>Thrombosis Research</i> , 2020, 191, S85-S90.	0.8	3
29	Latest advances in preventing thromboembolic disease in the ambulatory oncology patient. <i>Thrombosis Research</i> , 2020, 191, S91-S98.	0.8	2
31	Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020, 191, S50-S57.	0.8	13
32	Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer. <i>Cancers</i> , 2020, 12, 2070.	1.7	7
33	Genes and proteins associated with the risk for cancer-associated thrombosis. <i>Thrombosis Research</i> , 2020, 191, S43-S49.	0.8	6
34	Thrombosis in hematological malignancies: mechanisms and implications. <i>Thrombosis Research</i> , 2020, 191, S58-S62.	0.8	14
35	Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Cancers</i> , 2020, 12, 2028.	1.7	17
36	Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2020, 191, S79-S84.	0.8	22
37	Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life. <i>Thrombosis Research</i> , 2020, 191, S123-S127.	0.8	1
38	Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. <i>Thrombosis Research</i> , 2020, 191, S3-S11.	0.8	26
39	Venous thromboembolism in palliative care patients: what do we know?. <i>Thrombosis Research</i> , 2020, 191, S128-S132.	0.8	5
40	Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis. <i>Lancet Haematology</i> , the, 2020, 7, e583-e593.	2.2	34

#	ARTICLE	IF	CITATIONS
41	Management of Cancer-Associated Thrombosis. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	1
42	Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Advances, 2020, 4, 5215-5225.	2.5	35
43	Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels. Cancer Medicine, 2020, 9, 8062-8073.	1.3	23
44	Central Venous Catheter Thrombosis in Cancer: A Multi-Centre Retrospective Study Investigating Risk Factors and Contemporary Trends in Management. Clinical Medicine Insights: Oncology, 2020, 14, 117955492095309.	0.6	13
45	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematology, the, 2020, 7, e746-e755.	2.2	21
46	Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis. Internal Medicine Journal, 2022, 52, 272-281.	0.5	14
47	Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives. Expert Review of Cardiovascular Therapy, 2020, 18, 791-800.	0.6	6
48	Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional Study. Cancers, 2020, 12, 2256.	1.7	19
49	Thrombosis and Hemostasis Issues in Cancer Patients with COVID-19. Seminars in Thrombosis and Hemostasis, 2020, 46, 785-788.	1.5	17
50	Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. The Cochrane Library, 2020, 2020, CD008500.	1.5	18
51	Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. Frontiers in Cardiovascular Medicine, 2020, 7, 568720.	1.1	5
52	Prophylaxis of venous thromboembolism in general surgery in Spain. Analysis of a national survey. Cirug�a Espa�ola (English Edition), 2020, 98, 516-524.	0.1	0
53	Profilaxis del tromboembolismo venoso en cirug�a general en Espa�a. An�lisis de una encuesta nacional. Cirug�a Espa�ola, 2020, 98, 516-524.	0.1	3
55	Debate: Thromboprophylaxis should be considered in all patients with cancer - No. Thrombosis Research, 2020, 191, 34-35.	0.8	2
56	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 1128-1136.	1.8	93
57	Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey. Oncologist, 2020, 25, e1091-e1097.	1.9	10
58	Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care. Cancers, 2020, 12, 1167.	1.7	5
59	Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants. Thrombosis and Haemostasis, 2020, 120, 899-911.	1.8	13

#	ARTICLE	IF	CITATIONS
60	Gastrointestinal metastatic breast cancer unmasked by anticoagulation. <i>Current Problems in Cancer Case Reports</i> , 2020, 1, 100002.	0.1	2
61	Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm. <i>Cancers</i> , 2020, 12, 1144.	1.7	18
62	The 2019 ESC guidelines on pulmonary embolism: some further insights. <i>European Journal of Internal Medicine</i> , 2020, 77, 6-8.	1.0	1
63	Cardiac calcified amorphous tumour associated with multiple myeloma. <i>BMJ Case Reports</i> , 2020, 13, e233679.	0.2	1
64	Incidence, Therapy, and Bleeding Risk—Cancer-Associated Thrombosis in Patients with Glioblastoma. <i>Cancers</i> , 2020, 12, 1354.	1.7	9
65	Tratamiento de la trombosis venosa profunda de extremidades inferiores. <i>Revista Clinica Espanola</i> , 2020, 220, 57-68.	0.2	0
66	Dynamic prediction modeling for cancer-associated venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1276-1277.	1.9	1
67	Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 550-561.	1.0	69
68	Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 380-388.	1.4	14
69	Thromboprophylaxis in the End-of-Life Cancer Care: The Update. <i>Cancers</i> , 2020, 12, 600.	1.7	7
70	Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. <i>Cancers</i> , 2020, 12, 618.	1.7	16
71	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1599-1607.	13.9	658
72	Preventing Venous Thromboembolism in Ambulatory Patients with Cancer: A Narrative Review. <i>Cancers</i> , 2020, 12, 612.	1.7	5
73	Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas. <i>Cancers</i> , 2020, 12, 432.	1.7	11
74	Prognosis in patients with cancer-associated venous thromboembolism: Comparison of the RIETE-VTE and modified Ottawa score. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1154-1161.	1.9	8
75	Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials. <i>Thrombosis Research</i> , 2020, 194, 57-65.	0.8	16
76	Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?. <i>Blood</i> , 2020, 136, 669-673.	0.6	4
77	Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?. <i>Cancers</i> , 2020, 12, 367.	1.7	15

#	ARTICLE	IF	CITATIONS
78	The guidelines they are a changinâ€™™. European Journal of Internal Medicine, 2020, 74, 5-7.	1.0	0
79	Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). JMV-Journal De Medecine Vasculaire, 2020, 45, 28-40.	0.1	3
80	Prevention of venous thromboembolism in medical cancer patients: Guidance or guideline?. Journal of Thrombosis and Haemostasis, 2020, 18, 520-521.	1.9	0
81	Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies. Leukemia and Lymphoma, 2020, 61, 1277-1291.	0.6	7
82	Spotlight in Plastic Surgery: April 2020. Plastic and Reconstructive Surgery, 2020, 145, 1105-1108.	0.7	0
83	Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status. Clinical and Translational Oncology, 2020, 22, 2026-2031.	1.2	8
84	Risk assessment of venous thromboembolism in hematological cancer patients: a review. Expert Review of Hematology, 2020, 13, 471-480.	1.0	4
85	Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?. Cancers, 2020, 12, 917.	1.7	11
86	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data metaâ€™analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1940-1951.	1.9	60
87	Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma â€™specific venous thrombosis prediction models. American Journal of Hematology, 2020, 95, 918-926.	2.0	8
88	Cancerâ€™associated venous thromboembolism: Treatment and prevention with rivaroxaban. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 532-549.	1.0	10
89	Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962091829.	0.7	8
90	Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer. Journal of Thrombosis and Thrombolysis, 2021, 51, 102-111.	1.0	8
91	A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 923-933.	2.0	52
92	Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. Journal of Thrombosis and Thrombolysis, 2021, 51, 419-429.	1.0	33
93	Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement. Gynecologic Oncology, 2021, 160, 312-321.	0.6	15
94	Update on Guidelines for the Management of Cancer-Associated Thrombosis. Oncologist, 2021, 26, e24-e40.	1.9	76
95	Prediction and Prevention of Cancer-Associated Thromboembolism. Oncologist, 2021, 26, e2-e7.	1.9	33

#	ARTICLE	IF	CITATIONS
96	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 616-624.	1.8	55
97	Deep vein thrombosis and brain metastases. Case report and systematic review. <i>Thrombosis Research</i> , 2021, 197, 195-201.	0.8	1
98	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 629-658.	1.2	144
99	An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 583-594.	0.9	4
100	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103125.	2.0	11
101	Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 489-501.	1.9	14
102	Venous thromboembolism in cancer patients: a population-based cohort study. <i>Blood</i> , 2021, 137, 1959-1969.	0.6	277
103	Venous Thromboembolism Prophylaxis with Low-Molecular-Weight Heparin in Primary Central Nervous System Lymphoma. <i>Oncology Research and Treatment</i> , 2021, 44, 52-57.	0.8	2
104	Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 697-708.	1.2	0
105	Update on extended prophylaxis for venous thromboembolism following surgery for gynaecological cancers. <i>Thrombosis Update</i> , 2021, 2, 100038.	0.4	3
106	Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study. <i>Journal of Cancer Science and Clinical Therapeutics</i> , 2021, 05, .	0.2	2
107	Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962097957.	0.7	2
108	Adverse Events in iBT and Their Clinical Management. , 2021, , 219-234.		0
109	Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962097548.	0.7	5
110	Highly stable surface-enhanced Raman spectroscopy assay on abnormal thrombin levels in the blood plasma of cancer patients. <i>Analytical Methods</i> , 2021, 13, 4328-4333.	1.3	6
111	Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies. <i>Oncologist</i> , 2021, 26, 427-432.	1.9	26
112	The incidence of asymptomatic thrombosis related to peripherally inserted central catheter in adults: A systematic review and meta-analysis Peopleâ€™s. <i>Nursing Open</i> , 2021, 8, 2249-2261.	1.1	14
113	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. <i>Blood Advances</i> , 2021, 5, 927-974.	2.5	431

#	ARTICLE	IF	CITATIONS
114	Effect of unfractionated heparin and low molecular weight heparin on the clotting of platelet-reduced whole blood: an in-vitro study utilizing thromboelastography. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 305-311.	0.5	1
115	Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism. <i>JAMA Network Open</i> , 2021, 4, e2036304.	2.8	24
116	Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients. <i>Blood Advances</i> , 2021, 5, 1050-1058.	2.5	5
117	Inhibition of Tumor-Host Cell Interactions Using Synthetic Heparin Mimetics. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 7080-7093.	4.0	14
118	The timing of venous thromboembolism in ovarian cancer patients: A nationwide Danish cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 992-1000.	1.9	13
119	Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia – A case-based review of clinical management. <i>Thrombosis Research</i> , 2021, 199, 38-42.	0.8	6
120	Current status of treatment of cancer-associated venous thromboembolism. <i>Thrombosis Journal</i> , 2021, 19, 21.	0.9	23
121	Letter to the editors-in-chief reply to: Solinas et al. Venous and arterial thromboembolic events with immune check point inhibitors: A systematic review. <i>Thrombosis Research</i> , 2021, 208, 214-216.	0.8	4
122	Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery. <i>Postgraduate Medicine</i> , 2021, 133, 20-26.	0.9	7
123	Checkpoint inhibitors and thrombosis: what's up?. <i>Blood</i> , 2021, 137, 1569-1570.	0.6	1
124	Risk factors of deep vein thrombosis of lower extremity in patients undergone gynecological laparoscopic surgery: what should we care. <i>BMC Women's Health</i> , 2021, 21, 130.	0.8	12
125	Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1250-1258.	1.9	34
126	Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 911-918.	0.5	2
127	Enoxaparina en el tratamiento de la tromboembolia venosa: estudio observacional de práctica clínica habitual. <i>Medicina Clinica Practica</i> , 2021, 4, 100189.	0.2	0
128	Arterial Thromboembolism in Cancer Patients. <i>JACC: CardioOncology</i> , 2021, 3, 205-218.	1.7	33
129	Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 634291.	1.1	6
130	Venous and Arterial Thromboembolism in Patients With Cancer. <i>JACC: CardioOncology</i> , 2021, 3, 173-190.	1.7	67
131	Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma. <i>Neurosurgical Review</i> , 2022, 45, 451-457.	1.2	14



#	ARTICLE	IF	CITATIONS
132	A narrative review on the epidemiology, prevention, and treatment of venous thromboembolic events in the context of chronic venous disease. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 1557-1567.	0.9	9
133	Cancer and Clot. <i>JACC: CardioOncology</i> , 2021, 3, 219-220.	1.7	1
134	Management of Cancer-Associated Venous Thrombosis: A Nationwide Survey among Danish Oncologists. <i>TH Open</i> , 2021, 05, e188-e194.	0.7	2
135	Burden of venous thromboembolism in patients with pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 2325-2340.	1.4	6
136	Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer. <i>Current Medical Research and Opinion</i> , 2021, 37, 1467-1482.	0.9	3
137	Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. <i>European Journal of Cancer</i> , 2021, 148, 371-381.	1.3	38
138	Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIMaLine): A two-center open-label pilot randomized controlled trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12517.	1.0	8
139	Treatment of venous thromboembolism in cancer patients: The dark side of the moon. <i>Cancer Treatment Reviews</i> , 2021, 96, 102190.	3.4	14
140	Effect of inferior vena cava filters on pulmonary embolism-related mortality and major complications: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 792-800.e2.	0.9	18
141	Cancer-Associated Thrombosis: A New Light on an Old Story. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 34.	1.0	8
142	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021, 202, 151-154.	0.8	11
143	Risk Assessment Models for Thrombosis and Anticoagulant-Related Bleeding in Ambulatory Cancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 972-981.	1.5	6
144	Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (A-GHO). <i>Cancers</i> , 2021, 13, 2905.	1.7	7
145	Contrasts in Glioblastoma—Venous Thromboembolism versus Bleeding Risk. <i>Cells</i> , 2021, 10, 1414.	1.8	5
146	Acute Hospital Mortality of Venous Thromboembolism in Patients With Cancer From Registry Data. <i>Journal of the American Heart Association</i> , 2021, 10, e019373.	1.6	12
147	Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 973-989.	1.3	10
148	Cancer and Thrombosis: New Treatments, New Challenges. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 41.	1.3	4
149	A nomogram model to predict the venous thromboembolism risk after surgery in patients with gynecological tumors. <i>Thrombosis Research</i> , 2021, 202, 52-58.	0.8	14

#	ARTICLE	IF	CITATIONS
150	Cancer-Associated Splanchnic Vein Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 931-941.	1.5	8
151	Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer. <i>Thrombosis Journal</i> , 2021, 19, 37.	0.9	2
153	The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study. <i>Cancers</i> , 2021, 13, 2884.	1.7	11
154	Cardiovascular events in cancer patients with bone metastases—A Danish population-based cohort study of 23,113 patients. <i>Cancer Medicine</i> , 2021, 10, 4885-4895.	1.3	6
155	Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2022, 97, 308-324.	1.4	16
156	Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. <i>Thrombosis and Haemostasis</i> , 2022, 122, 633-645.	1.8	7
157	Racial differences in symptomatic postoperative venous thromboembolism rates after major oncologic resection. <i>Surgery</i> , 2021, 170, 1770-1776.	1.0	1
158	Venous thromboembolism. <i>Lancet</i> , The, 2021, 398, 64-77.	6.3	243
159	Construction and Validation of a Nomogram for Predicting the Risk of Deep Vein Thrombosis in Hepatocellular Carcinoma Patients After Laparoscopic Hepatectomy: A Retrospective Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 783-794.	1.8	4
160	Safety of liver resection in patients receiving antithrombotic therapy: A systematic review of the literature. <i>World Journal of Hepatology</i> , 2021, 13, 804-814.	0.8	3
161	A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12545.	1.0	9
162	Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 417-424.	1.0	4
163	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021, 05, e376-e386.	0.7	18
164	Patient education program at the forefront of cancer-associated thrombosis care. <i>JMV-Journal De Medecine Vasculaire</i> , 2021, 46, 215-223.	0.1	2
165	Safety of pancreatic surgery with special reference to antithrombotic therapy: A systematic review of the literature. <i>World Journal of Clinical Cases</i> , 2021, 9, 6747-6758.	0.3	4
166	Current state of non-hematologic cancer-associated thrombosis at a tertiary care hospital in India. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, , .	0.1	1
168	Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?. <i>Neuro-Oncology</i> , 2022, 24, 455-464.	0.6	11
169	Uterine rhabdomyosarcoma complicated by cerebral venous thrombosis and uterine inversion in a young woman: case report and literature review. <i>BMC Women's Health</i> , 2021, 21, 314.	0.8	3

#	ARTICLE	IF	CITATIONS
170	Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. <i>Thrombosis and Haemostasis</i> , 2022, 122, 818-829.	1.8	23
171	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3008-3017.	1.9	10
172	Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. <i>Thrombosis and Haemostasis</i> , 2022, 122, 796-807.	1.8	21
173	The Role of Direct Oral Anticoagulants in Cancer-Associated Thrombosis According to the Current Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 960.	0.8	1
174	Syncope as the initial presentation of pulmonary embolism in two patients with hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e27211.	0.4	1
175	A systematic review and meta-analysis of outcomes after acute limb ischemia in patients with cancer. <i>Journal of Vascular Surgery</i> , 2021, 74, 1033-1040.e1.	0.6	6
176	Risk Factors for Catheter-Related Thrombosis in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Medicina (Lithuania)</i> , 2021, 57, 1020.	0.8	3
177	A systematic review of apixaban in prevention and treatment of cancer-associated venous thromboembolism. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e26-e38.	0.7	1
178	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 646-656.	1.8	25
179	Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 1-5.	0.2	0
180	A drug utilization study of oral anticoagulants in five representative cities of China between 2015 and 2019. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, , .	0.7	2
181	Risk assessment models of cancer-associated thrombosis - Potentials and perspectives. <i>Thrombosis Update</i> , 2021, 5, 100075.	0.4	11
182	Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1061-1070.	1.8	4
183	Evaluation of the Khorana, PROTECHT, and 5â€¦NP scores for prediction of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2974-2983.	1.9	14
184	The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2791-2800.	1.9	7
185	Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 4603.	1.7	10
186	Role of Sciellin in gallbladder cancer proliferation and formation of neutrophil extracellular traps. <i>Cell Death and Disease</i> , 2021, 12, 30.	2.7	19
187	Traitement. , 2021, , 209-228.		0

#	ARTICLE	IF	CITATIONS
189	Prediction and Diagnosis of Venous Thromboembolism Using Artificial Intelligence Approaches: A Systematic Review and Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110211.	0.7	10
191	Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. <i>BMJ Open</i> , 2020, 10, e039057.	0.8	7
192	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 71-79.	0.9	9
193	Clinical characteristics and 3-month outcomes in cancer patients with incidental <i>versus</i> clinically suspected and confirmed pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 58, 2002723.	3.1	9
194	Factor Xa inhibitors in the prevention of cancer-related venous thromboembolism: lessons learned by clinical trials. <i>Future Oncology</i> , 2020, 16, 2591-2594.	1.1	2
195	Rate of venous thromboembolism and atrial fibrillation in a real-world case series of advanced cancer patients: the CaTEV Study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 444-452.	0.6	3
196	Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis. <i>Cancers</i> , 2020, 12, 1291.	1.7	18
197	Incidence and risk factors for venous thromboembolism following craniotomy for intracranial tumors: A cohort study. <i>Journal of Innovative Optical Health Sciences</i> , 2020, 15, 31-38.	0.5	8
198	Systematic reviews of observational studies of Risk of Thrombosis and Bleeding in General and Gynecologic Surgery (ROTBIGGS): introduction and methodology. <i>Systematic Reviews</i> , 2021, 10, 264.	2.5	9
199	Risk assessment for recurrent venous thromboembolism in patients with cancer. <i>Thrombosis Update</i> , 2021, 5, 100080.	0.4	5
200	Stroke Prevention After Cryptogenic Stroke. <i>Current Cardiology Reports</i> , 2021, 23, 174.	1.3	9
201	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021, 208, 79-82.	0.8	4
202	Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. <i>Supportive Care in Cancer</i> , 2022, 30, 2919-2931.	1.0	8
203	Anticoagulants oraux directs dans la maladie thromboembolique veineuse associée aux cancers. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2020, 2020, 2-8.	0.0	0
204	Anticoagulation therapy in cancer associated thromboembolism - new studies, new guidelines. <i>Vnitřní Lekarství</i> , 2020, 66, 225-231.	0.1	1
205	The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines. <i>Thrombosis Journal</i> , 2021, 19, 76.	0.9	5
206	Impact of Pregnancy-Related Venous Thromboembolism on Quality of Patients's Lives. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110408.	0.7	0
207	PROPHYLAXIS OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ACTIVE ONCOLOGICAL DISEASE, RECEIVING MEDICAL ANTI-CANCER CHEMOTHERAPY IN OUTPATIENT CONDITIONS. ROLE OF APIXABAN. <i>Atherothrombosis</i> , 2020, , 46-54.	0.1	1

#	ARTICLE	IF	CITATIONS
209	The possibilities of using new (direct) oral anticoagulants in oncology. <i>Onkologie (Czech Republic)</i> , 2020, 14, 172-177.	0.0	0
210	Right Atrial Thrombosis and Pulmonary Embolism: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 895-907.	1.5	7
211	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. <i>TH Open</i> , 2020, 04, e446-e456.	0.7	11
212	Profilaxis de la enfermedad tromboembólica venosa en pacientes con cáncer. <i>Revista Clinica Espanola</i> , 2020, 220, 17-24.	0.2	3
214	The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 1076029620940046.	0.7	0
215	Extended anticoagulation treatment for cancer-associated thrombosis: Rates of recurrence and bleeding beyond 6 months: A systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 619-634.	1.9	22
216	Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2267-2283.	1.1	7
217	Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH/SETH. <i>Clinical and Translational Oncology</i> , 2022, 24, 770-783.	1.2	1
218	Coagulopathies in Intensive Care Medicine: Balancing Act between Thrombosis and Bleeding. <i>Journal of Clinical Medicine</i> , 2021, 10, 5369.	1.0	7
219	Cancer-Associated Thrombosis: Patient-Reported Outcomes With Rivaroxaban (COSIMO) - Baseline characteristics and clinical outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12604.	1.0	3
220	Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung Cancer. <i>Thrombosis Journal</i> , 2021, 19, 95.	0.9	7
222	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. <i>Haematologica</i> , 2022, 107, 1567-1576.	1.7	14
223	Evidence-based Appraisal of the CARAVAGGIO Trial. <i>Journal of Contemporary Pharmacy Practice</i> , 2021, 68, 18-23.	0.2	0
224	Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial. <i>International Journal of Hematology</i> , 2022, , 1.	0.7	4
225	Resolution of acute pulmonary embolism using anticoagulation therapy alone in coronavirus disease 2019. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 578-584.e2.	0.9	8
226	Practical treatment guidance for cancer-associated thrombosis - Managing the challenging patient: A consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103599.	2.0	6
227	Coagulome and the tumor microenvironment: an actionable interplay. <i>Trends in Cancer</i> , 2022, 8, 369-383.	3.8	44
229	Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors. <i>Current Problems in Cancer</i> , 2022, 46, 100832.	1.0	2

#	ARTICLE	IF	CITATIONS
230	Molecular Landscape of the Coagulome of Oral Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 460.	1.7	12
231	Public Awareness on Cancer-Associated Thrombosis among the Greek Population: First Findings from the ROADMAP-CAT Awareness Study. <i>TH Open</i> , 2022, 06, e89-e95.	0.7	3
232	Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. <i>Blood Advances</i> , 2022, 6, 2967-2976.	2.5	23
233	Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden. <i>BMC Urology</i> , 2022, 22, 15.	0.6	0
234	Pulmonary embolism – An EFIM guideline critical appraisal and adaptation for practicing clinicians. <i>European Journal of Internal Medicine</i> , 2022, 96, 5-12.	1.0	7
235	Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with ovarian cancer receiving chemotherapy. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 1-5.	0.2	0
236	How Strong Is the Evidence Supporting Thromboprophylaxis in Surgical Oncology?. <i>Journal of Clinical Oncology</i> , 2022, 40, 320-323.	0.8	3
237	Pharmacological and interventional management of pulmonary embolism: where do we stand?. <i>Future Cardiology</i> , 2022, 18, 191-206.	0.5	3
238	Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A <sc>SEER&#x2013;Medicare</sc> analysis. <i>Cancer Medicine</i> , 2022, 11, 1817-1826.	1.3	6
239	Trousseau's Syndrome in 19th Century Qing Dynasty Paintings of Breast Tumors: Early Insights into Cancer and Thrombosis Risk. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 991-994.	1.5	2
240	Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 336-343.	2.3	6
241	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. <i>Liver International</i> , 2022, 42, 1229-1240.	1.9	17
242	Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow-up. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1166-1181.	1.9	23
243	Knowledge, attitudes, and practices regarding venous thromboembolism prophylaxis. <i>Medicine (United States)</i> , 2021, 100, e28016.	0.4	4
244	Construction of Risk Assessment Model for Venous Thromboembolism After Colorectal Cancer Surgery: A Chinese Single-Center Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110737.	0.7	7
245	Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210829.	0.7	7
246	Herz-Kreislauf-System. , 2022, , 181-246.		0
247	Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients. <i>Current Oncology Reports</i> , 2022, 24, 493-500.	1.8	3

#	ARTICLE	IF	CITATIONS
248	Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1594-1602.	1.8	8
249	Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence. <i>European Journal of Internal Medicine</i> , 2022, 100, 33-45.	1.0	8
250	Venous thromboembolism and radiation therapy: The final <sc>radiation-induced</sc> thrombosis study analysis. <i>Cancer Medicine</i> , 2022, 11, 1753-1762.	1.3	13
251	Cancer-associated venous thromboembolism. <i>Nature Reviews Disease Primers</i> , 2022, 8, 11.	18.1	130
252	Evaluation of the Khorana Predictive Thrombotic Risk and Thromboprophylaxis Score in Cancer Patients in a Third Level Hospital. <i>Open Respiratory Archives</i> , 2022, , .	0.0	0
253	Relevant pharmacologic interactions in the concurrent management of brain tumor-related epilepsy and venous thromboembolism: a systematic review. <i>Journal of Neuro-Oncology</i> , 2022, , 1.	1.4	1
254	Asymptomatic pulmonary thromboembolism diagnosed based on prolonged fever after gastric cancer surgery: A case report with literature review. <i>International Journal of Surgery Case Reports</i> , 2022, 92, 106836.	0.2	0
255	Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel. <i>PLoS ONE</i> , 2022, 17, e0264653.	1.1	5
256	The Best Evidence for the Prevention and Management of Lower Extremity Deep Venous Thrombosis After Gynecological Malignant Tumor Surgery: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Surgery</i> , 2022, 9, 841275.	0.6	2
257	Impact of Antithrombotic Therapy on the Outcome of Patients Undergoing Laparoscopic Colorectal Cancer Surgery: A Systematic Literature Review. <i>Cureus</i> , 2022, 14, e23390.	0.2	0
258	Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 727487.	1.1	18
259	Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism. <i>Frontiers in Pharmacology</i> , 2022, 13, 810455.	1.6	0
260	Anticoagulants decrease the risk for catheter-related venous thrombosis in patients with chronic intestinal failure: A long-term cohort study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 1677-1685.	1.3	6
261	The impact of advanced age on anticoagulant therapy for acute venous thromboembolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 27-37.	1.5	2
262	Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions. <i>Frontiers in Pharmacology</i> , 2022, 13, 757415.	1.6	0
263	Cancer Therapies and Vascular Toxicities. <i>Current Treatment Options in Oncology</i> , 2022, 23, 333-347.	1.3	6
264	Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study. <i>Gynecologic Oncology</i> , 2022, 165, 75-81.	0.6	1
265	Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1647-1658.	0.8	46

#	ARTICLE	IF	CITATIONS
266	Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview. <i>Clinical and Experimental Medicine</i> , 2023, 23, 313-331.	1.9	21
268	Machine learning predicts cancer-associated deep vein thrombosis using clinically available variables. <i>International Journal of Medical Informatics</i> , 2022, 161, 104733.	1.6	17
269	Safety and Efficacy of Low Molecular Weight Heparin for Thromboprophylaxis in the Elderly: A Network Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 783104.	1.6	1
270	Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials. <i>Heart Lung and Circulation</i> , 2022, 31, 716-725.	0.2	1
271	Publisher note. <i>Thrombosis Research</i> , 2021, 208, 173-175.	0.8	2
272	How well do European patients understand cancer-associated thrombosis? A patient survey. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100557.	0.7	4
274	ABO blood group type and risk of venous thromboembolism in patients with cancer. <i>Blood Advances</i> , 2022, 6, 6274-6281.	2.5	17
275	In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients. <i>Cancers</i> , 2022, 14, 1937.	1.7	9
276	Low-dose apixaban in extended treatment of cancer-associated thrombosis: Less is more?. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1070-1072.	1.9	1
277	Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1665-1673.	1.9	16
279	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. <i>Haematologica</i> , 2021, , .	1.7	0
281	Venous Thromboembolism In Cancer Patients: "From Evidence to Care". <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210987.	0.7	2
282	Challenging issues in the management of cancer-associated venous thromboembolism. <i>Blood Research</i> , 2022, 57, S44-S48.	0.5	1
283	A Systematic Review of the Guidelines on Venous Thromboembolism Prophylaxis in Gynecologic Oncology. <i>Cancers</i> , 2022, 14, 2439.	1.7	4
284	Cancer-Associated Deep Vein Thrombosis: Insights from Randomized Trials and Real-Life Practice. <i>Flebologiya</i> , 2022, 16, 156.	0.2	1
285	Risk stratification for clinical severity of pulmonary embolism in patients with cancer: a narrative review and MASCC clinical guidance for daily care. <i>Supportive Care in Cancer</i> , 2022, , 1.	1.0	1
286	Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?. <i>Supportive Care in Cancer</i> , 2022, , .	1.0	0
287	Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study. <i>JMV-Journal De Medecine Vasculaire</i> , 2022, , .	0.1	0



#	ARTICLE	IF	CITATIONS
288	Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden. <i>BMJ Open</i> , 2022, 12, e055485.	0.8	2
289	Unanswered questions in cancer-associated thrombosis. <i>British Journal of Haematology</i> , 2022, 198, 812-825.	1.2	11
290	Cancer-associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	1
291	Building a CAT clinic - real-world systems approaches to prevention and treatment. <i>Thrombosis Research</i> , 2022, 213, S84-S86.	0.8	0
292	The impact of thromboprophylaxis with LMWHs on the survival of patients with pancreatic cancer. <i>Thrombosis Research</i> , 2022, 213, S120-S126.	0.8	3
293	A review of latest clinical practice guidelines for the management of cancer-associated thrombosis. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101348.	0.7	3
294	Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101347.	0.7	3
295	A Nomogram for Predicting Survival in Patients With Colorectal Cancer Incorporating Cardiovascular Comorbidities. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	3
296	Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. <i>Thrombosis Research</i> , 2022, 213, S66-S71.	0.8	7
297	Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	31
298	Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study). <i>Cancers</i> , 2022, 14, 2771.	1.7	4
299	Thromboprophylaxis of cancer patients undergoing systemic therapy in the ambulatory setting. <i>Best Practice and Research in Clinical Haematology</i> , 2022, , 101351.	0.7	0
300	Thromboembolic disease prevention before cancer therapy. , 2023, , 92-99.		0
301	Thromboembolic disease treatment during cancer therapy. , 2023, , 162-174.		0
302	Pulmonary disease during cancer therapy. , 2023, , 200-204.		0
303	Treatment modalities in cancer-associated venous thromboembolism (VTE). <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101354.	0.7	2
304	Thrombosis and bleeding in hematological malignancy. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101353.	0.7	7
305	Extended Anticoagulation After Pulmonary Embolism: A Multicenter Observational Cohort Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	5

#	ARTICLE	IF	CITATIONS
306	DOACs or VKAs or LMWH – What is the optimal regimen for cancer-associated venous thromboembolism? A systematic review and meta-analysis. <i>Annals of Medicine and Surgery</i> , 2022, 79, .	0.5	1
307	Venous thromboembolic prophylaxis. , 2022, , 161-175.		0
309	The Ottawa Score Performs Poorly to Identify Cancer Patients at High Risk of Recurrent Venous Thromboembolism: Insights from the TROPIQUE Study and Updated Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3729.	1.0	1
310	Characteristics and Outcomes of Patients Consulted by a Multidisciplinary Pulmonary Embolism Response Team: 5-Year Experience. <i>Journal of Clinical Medicine</i> , 2022, 11, 3812.	1.0	1
311	Thromboprophylaxis in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2807-2815.	0.6	1
312	Treatment and Bleeding Complications of Cancer-Associated Venous Thromboembolism: A Korean Population-Based Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 2011-2018.	1.8	7
313	A Single Center Retrospective Cohort Study Comparing Different Anticoagulants for the Treatment of Catheter-Related Thrombosis of the Upper Extremities in Women With Gynecologic and Breast Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
314	EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. <i>HemaSphere</i> , 2022, 6, e750.	1.2	29
315	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. <i>Lancet Oncology</i> , The, 2022, 23, e334-e347.	5.1	138
316	Commentary: A guide for what we know and what still needs to be learned. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, , .	0.4	0
317	Correlation of Inflammation and Coagulation Markers with the Incidence of Deep Vein Thrombosis in Cancer Patients with High Risk of Thrombosis. <i>International Journal of General Medicine</i> , 0, Volume 15, 6215-6226.	0.8	7
318	Perioperative Care: Sarcoma and Melanoma. , 2023, , 343-350.		0
319	–Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients–30 months follow– Comment from Serrao et al.. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1935-1937.	1.9	3
320	Safety of Direct Acting Oral Anticoagulants (DOACs) in Comparison to Enoxaparin in Gastrointestinal and Genito-Urinary Cancers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
321	Catheter-related thrombosis (CRT) in patients with solid tumors: a narrative review and clinical guidance for daily care. <i>Supportive Care in Cancer</i> , 2022, 30, 8577-8588.	1.0	6
322	Complexity and clinical significance of drug–drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT). <i>Supportive Care in Cancer</i> , 2022, 30, 8559-8573.	1.0	9
324	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, e333-e465.	0.5	97
325	Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis. <i>European Journal of Internal Medicine</i> , 2022, 105, 30-37.	1.0	9

#	ARTICLE	IF	CITATIONS
327	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>European Heart Journal</i> , 2022, 43, 4229-4361.	1.0	705
328	Characteristics and predictors of venous thrombosis recurrence in patients with cancer and catheter-related thrombosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12761.	1.0	5
329	Impact of hereditary thrombophilia on cancer-associated thrombosis, tumour susceptibility and progression: A review of existing evidence. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188778.	3.3	8
330	Venous thromboembolism in cancer and cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 178, 103782.	2.0	9
331	A case of monoclonal gammopathy of undetermined significance and minimal change disease complicated by bilateral pulmonary emboli. <i>SAGE Open Medical Case Reports</i> , 2022, 10, 2050313X2211176.	0.2	0
332	The 2022 ITAC evidence-based clinical practice guidelines: New update from the International Initiative on Thrombosis and Cancer to improve the care in patients with cancer-associated thrombosis. <i>JMV-Journal De Medecine Vasculaire</i> , 2022, 47, 113-115.	0.1	0
333	Establishment of a mouse model for ovarian cancer-associated venous thromboembolism. <i>Experimental Biology and Medicine</i> , 2023, 248, 26-35.	1.1	0
334	The ICU-venous thromboembolism score and tumor grade can predict in-hospital venous thromboembolism occurrence in critical patients with tumors. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
335	Preoperative and postoperative clinical signatures of postgastrectomy venous thromboembolism in patients with gastric cancer: A retrospective cohort study. <i>Asian Journal of Surgery</i> , 2023, 46, 1556-1563.	0.2	1
336	Approach to Thromboprophylaxis for Prevention of Venous Thromboembolism in COVID-19: Global Updates and Clinical Insights from India. <i>Clinics and Practice</i> , 2022, 12, 766-781.	0.6	2
339	Anticoagulant use and associated outcomes in older patients receiving home palliative care: a retrospective cohort study. <i>Cmaj</i> , 2022, 194, E1198-E1208.	0.9	4
340	Concomitant Deep Vein Thrombosis in Cancer Patients with Unsuspected Pulmonary Embolism. <i>Cancers</i> , 2022, 14, 4510.	1.7	0
341	Pulmonary Embolism in the Cancer Associated Thrombosis Landscape. <i>Journal of Clinical Medicine</i> , 2022, 11, 5650.	1.0	8
342	Practical Considerations for the Management of Cancer-Associated Venous Thromboembolism: A Guide for the General Oncology Practitioner. <i>Current Oncology</i> , 2022, 29, 6419-6432.	0.9	1
344	Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. <i>Neuro-Oncology</i> , 2023, 25, 4-25.	0.6	45
346	Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. <i>Cells</i> , 2022, 11, 3214.	1.8	17
348	Subgroup analyses in venous thromboembolism trials reporting pharmacological interventions: A systematic review. <i>Thrombosis Research</i> , 2023, 232, 151-159.	0.8	1
350	Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	1

#	ARTICLE	IF	CITATIONS
351	Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation. <i>Journal of Clinical Medicine</i> , 2022, 11, 5970.	1.0	1
352	Cabozantinib safety with different anticoagulants in patients with renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	1
353	Association of Prophylaxis and Length of Stay With Venous Thromboembolism in Abdominopelvic Surgery. <i>Journal of Surgical Research</i> , 2023, 282, 198-209.	0.8	0
354	Is new risk assessment score of venous thromboembolism for hospitalized surgical patients with borderline resectable pancreatic adenocarcinoma needed?. <i>Asian Journal of Surgery</i> , 2022, , .	0.2	1
356	Starting a minimally invasive inguinal lymphadenectomy program: Initial learning experience and outcomes. <i>Surgery</i> , 2022, , .	1.0	0
357	Oral Squamous Cell Carcinoma-Associated Thrombosis: What Evidence?. <i>Cancers</i> , 2022, 14, 5616.	1.7	1
358	Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy. <i>Thrombosis Research</i> , 2023, 221, 164-172.	0.8	4
359	Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma. <i>JACC: CardioOncology</i> , 2022, 4, 522-531.	1.7	12
360	Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice. <i>Thrombosis Research</i> , 2022, 220, 145-152.	0.8	2
361	A Review of the Past, Present and Future of Cancer-associated Thrombosis Management. <i>Heart International</i> , 2022, 16, 117.	0.4	2
362	Causal relationship between 14 site-specific cancers and venous thromboembolism. , 2022, 1, 316-327.		2
363	Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study. <i>Supportive Care in Cancer</i> , 2023, 31, .	1.0	0
364	Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
365	The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study. <i>TH Open</i> , 2023, 07, e14-e29.	0.7	0
366	A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK. <i>Current Medical Research and Opinion</i> , 2023, 39, 483-495.	0.9	0
367	DOAC in the treatment of cancer-associated venous thromboembolism: a retrospective cohort study beyond the guidelines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5773-5779.	1.2	1
368	Prophylactic Anticoagulation in Patients With Pancreatic Adenocarcinoma: A Single Tertiary Care Center Retrospective QI Project. <i>Anticancer Research</i> , 2023, 43, 137-141.	0.5	0
369	Survey of medical oncologists and trainee practice on venous thromboembolism prophylaxis and treatment in solid cancers. <i>Internal Medicine Journal</i> , 2023, 53, 131-135.	0.5	1

#	ARTICLE	IF	CITATIONS
370	Drug-Drug Interactions in the Treatment of Cancer-Associated Venous Thromboembolism with Direct Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2024, 50, 489-498.	1.5	1
371	The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers. <i>Cancers</i> , 2023, 15, 1531.	1.7	0
372	Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. <i>Gynecologic Oncology</i> , 2023, 172, 9-14.	0.6	3
374	Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 294-302.	1.9	5
375	Right needle, right patient, right time? A national flash-mob audit of thromboprophylaxis in palliative care. <i>Thrombosis Research</i> , 2023, 223, 95-101.	0.8	1
376	Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. <i>Expert Review of Hematology</i> , 2023, 16, 131-140.	1.0	3
377	Real-World Analysis of the Safety and Effectiveness of Apixaban Therapy in Cancer Patients with Venous Thromboembolism in Saudi Arabia. , 2023, 2, 102-111.		0
378	Efficacy and safety of rivaroxaban for the treatment of PICC-related upper extremity deep vein thrombosis in cancer patients: a retrospective study. <i>Thrombosis Journal</i> , 2023, 21, .	0.9	4
379	A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 2911-2925.	0.8	13
380	Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism. <i>Thrombosis Journal</i> , 2023, 21, .	0.9	0
381	Lack of Funding for Direct-Acting Oral Anticoagulants for the Treatment of Pulmonary Embolism in Spain: Why and Until When. <i>Archivos De Bronconeumologia</i> , 2023, , .	0.4	0
382	Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles. <i>Biomolecules</i> , 2023, 13, 321.	1.8	2
383	Occurrence rates and risk factors of in-hospital venous thromboembolism, major bleeding, and death in patients receiving fondaparinux after orthopedic surgery or trauma surgery. <i>Irish Journal of Medical Science</i> , 2023, 192, 2973-2979.	0.8	1
384	Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer. <i>JAMA Network Open</i> , 2023, 6, e230010.	2.8	6
385	Perioperative Anticoagulation in Patients with Cancer. <i>Current Oncology Reports</i> , 2023, 25, 379-386.	1.8	0
386	To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice. <i>Advances in Hematology</i> , 2023, 2023, 1-7.	0.6	0
387	Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2023, , 38-49.	0.2	1
389	Oncologic Emergencies in Patients Undergoing Major Surgery. , 2023, , 125-134.		0

#	ARTICLE	IF	CITATIONS
390	Choice and Timing of Antithrombotic After Ischemic Stroke, Intracerebral Hemorrhage or Cerebral Venous Thrombosis. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, .	0.8	0
391	Vena-Cava-Filter. <i>Evidenzbasierte Chirurgie</i> , 2022, , 365-376.	0.0	0
392	Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch <sup>®</sup> ): a systematic review. <i>Journal of Neuro-Oncology</i> , 2023, 162, 267-293.	1.4	5
393	Incidentally Discovered Right Atrial Mass: A Rare and Unexpected Etiology. <i>Texas Heart Institute Journal</i> , 2023, 50, .	0.1	0
394	Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review. <i>BMJ Open Respiratory Research</i> , 2023, 10, e001493.	1.2	0
395	Advancing Tissue Factor-targeted Therapy for Osteosarcoma via Understanding its Role in the Tumor Microenvironment. <i>Current Pharmaceutical Design</i> , 2023, 29, 1009-1012.	0.9	1
396	An unexpected recurrence of rectal squamous cell cancer presenting as deep vein thrombosis. <i>Journal of Vascular Surgery Cases and Innovative Techniques</i> , 2023, 9, 101142.	0.3	1
403	Interventional therapies for pulmonary embolism. <i>Nature Reviews Cardiology</i> , 2023, 20, 670-684.	6.1	15
406	Newly diagnosed glioblastoma: A review on clinical management. , 2023, , 101-123.		0
449	Vena Cava Filter. , 2023, , 427-440.		0